A Phase 2 interventional study of Roflumilast and Desloratadine in Rheumatoid Arthritis, sponsored by Horus University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Horus University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Arthritis, Rheumatoid with a site in Egypt — 35 open to participants now, 36 under way, 9 of them phase 3. Arthritis, Rheumatoid · Egypt.
Among the 88 studies in Arthritis, Rheumatoid with a site in Egypt, this one is the 15th largest by planned enrollment of the 56 interventional ones that give a count, is one of 14 that started in 2026, is one of 12 in phase 2, reaches primary completion later than 30 of the 35 other live ones, and was the 79th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →35 of the 88 studies in Arthritis, Rheumatoid with a site in Egypt are open now. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 18+
Tanta University · Sites in Egypt
Ages 18–70
Horus University · Sites in Egypt
Ages 18–60
Horus University · Sites in Egypt
Ages 18–60
Tanta University · Sites in Egypt
Ages 18+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 22 · Phase 3 16 · Phase 4 5
First in 2010; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 68 across the 56 interventional studies, 98 across the 32 observational. Of the 39 that completed or were terminated, 4 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 88 have an industry lead sponsor. The 10 most frequent:
Horus University is the lead sponsor of 33 studies on the registry; 11 are open to participants now.
Horus University has 3 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
11 of the studies in Arthritis, Rheumatoid with a site in Egypt that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07800351Phase 3Tanta UniversityNicorandil in Atherosclerosis Risk in Patients With Rheumatoid Arthritis | 2027-02 |
| NCT07730723Phase 3Ain Shams UniversityThe Effect of Nicorandil on Rheumatoid Arthritis Patients | 2027-07 |
| NCT07401732Tanta UniversityDysphagia in Rheumatoid Arthritis | 2026-11 |
| NCT07632872Horus UniversityDesloratadine as Adjunct Therapy for Rheumatoid Arthritis | 2026-11 |
| NCT07814989Sohag UniversityWrist Nerve Block as a New Treatment in Patients With Rheumatoid Arthritis | 2027-01-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 88 studies in Arthritis, Rheumatoid with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and disability. Although standard disease-modifying antirheumatic drugs (DMARDs) are effective for many patients, some individuals continue to experience active disease and inflammation. The aim of this study is to evaluate the effectiveness and safety of adding either roflumilast or desloratadine to standard DMARD therapy in patients with rheumatoid arthritis. Participants will be randomly assigned to receive either roflumilast, desloratadine, or placebo in addition to their usual treatment. The study will assess changes in disease activity, inflammatory biomarkers, and patient-reported outcomes over a three-month follow-up period. The results of this study may help identify new add-on treatment options to improve disease control in patients with rheumatoid arthritis.
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovial inflammation, progressive joint destruction, and impaired quality of life. Despite the availability of conventional disease-modifying antirheumatic drugs (DMARDs), a subset of patients continues to have persistent disease activity and inflammatory burden.
Phosphodiesterase-4 inhibitors and antihistamines have demonstrated potential anti-inflammatory and immunomodulatory effects that may be beneficial in rheumatoid arthritis. Roflumilast, a selective phosphodiesterase-4 inhibitor, reduces the production of pro-inflammatory cytokines, while desloratadine has been shown to exhibit additional anti-inflammatory properties beyond its antihistaminic effect.
This randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the efficacy and safety of roflumilast or desloratadine as add-on therapy to standard DMARD treatment in patients with rheumatoid arthritis. Eligible participants will be randomized into three parallel groups to receive either roflumilast, desloratadine, or placebo for a duration of three months.
Clinical assessments will include evaluation of disease activity scores, inflammatory biomarkers, and patient-reported outcomes. Safety and tolerability will be monitored throughout the study period. The findings of this study may provide evidence for novel adjunctive therapeutic strategies in the management of rheumatoid arthritis.
Inclusion Criteria:
Exclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive roflumilast in addition to standard disease-modifying antirheumatic drug therapy.
Drug: Roflumilast
Participants will receive desloratadine in addition to standard disease-modifying antirheumatic drug therapy.
Drug: Desloratadine
Participants will receive placebo in addition to standard disease-modifying antirheumatic drug therapy.
Drug: Placebo
Roflumilast administered orally as add-on therapy to standard disease-modifying antirheumatic drugs
Desloratadine administered orally as add-on therapy to standard disease-modifying antirheumatic drugs.
Matching placebo administered orally as add-on therapy to standard disease-modifying antirheumatic drugs.
Change in Disease Activity Score (DAS28)
Disease activity will be assessed using the Disease Activity Score in 28 joints (DAS28), which is a composite index ranging from 0 to approximately 9.4. Higher DAS28 scores indicate greater disease activity. The primary outcome is the change in DAS28 score from baseline to 12 weeks.
Time frame: Baseline to 12 weeks
Change in serum inflammatory biomarkers
Change in serum levels of inflammatory biomarkers including interleukin-17 (IL-17), monocyte chemoattractant protein-1 (MCP 1), Cyclic adenosine monophosphate (cAMP), and malondialdehyde (MDA).
Time frame: Baseline to 12 weeks
Plan to share: Undecided
Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.
Of 42 non-industry phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 49. This study's planned 14 months is below that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Roflumilast · Desloratadine
Horus University